| Literature DB >> 31198240 |
Mohamed Maher El Baz1, Tamer El Metwally Farahat1.
Abstract
BACKGROUND AND AIMS: Intrarticular ingection of local anesthetics in the knee joint decreases postoperative pain after knee arthrosopy. Dexmedetomidine an α2 agonist has sedative and analgesic effects and decreases postoperative pain after knee arthroscopy when injected intraarticulary. Levobubivacaine is a long acting local anesthetic with less toxicity than bubivacaine. We compared the analgesic effects of dexmedetomidine when added to intraarticular levobupivacaine in patients posted for knee arthroscopy.Entities:
Keywords: Dexmedetomidine; evobupivacaine; intraarticular
Year: 2019 PMID: 31198240 PMCID: PMC6545963 DOI: 10.4103/aer.AER_23_19
Source DB: PubMed Journal: Anesth Essays Res ISSN: 2229-7685
Patients’ characteristics data (mean±standard deviation) or number
| Group C | Group L | Group LD | ||
|---|---|---|---|---|
| Age (years) | 24.9±4.6 | 25.5±4.5 | 25.6±74.7 | 1* |
| 0.18† | ||||
| 0.66‡ | ||||
| Weight (kg) | 70.2±5.8 | 70.7±6 | 67.6±6.4 | 1* |
| 0.21† | ||||
| 0.1‡ | ||||
| Sex (female/male) | 7/23 | 6/24 | 9/21 | |
| Duration of surgery (min) | 54±7.3 | 55±7 | 53±6.3 | 0.13* |
| 0.21† | ||||
| 1‡ | ||||
| ASA | ||||
| I | 25 | 24 | 26 | |
| II | 10 | 11 | 12 |
C=Control, L=Levobupivacaine, LD=Levobupivacaine dexmedetomidine group, ASA=American Society of Anesthesiologist. *Level of significance between Group C and Group L, †Level of significance between Group C and Group LD, ‡Level of significance between Group L and Group LD
Postoperative pain (data are in mean±standard deviation)
| Group C | Group L | Group LD | ||
|---|---|---|---|---|
| VAS30rest | 54.9±16.7 | 41.8±9.8 | 36.2±8.4 | 0.001* |
| <0.001† | ||||
| 0.022‡ | ||||
| VAS30mov | 58.3±16.4 | 44.7±10 | 39.2±8.3 | <0.001* |
| <0.001† | ||||
| 0.024‡ | ||||
| VAS1rest | 52.6±16.7 | 40.4±9.2 | 34.6±8.4 | 0.001* |
| <0.001† | ||||
| 0.014‡ | ||||
| VAS1mov | 56.9±17.1 | 43.5±9.6 | 37.6±8.6 | 0.001* |
| <0.001† | ||||
| 0.016‡ | ||||
| VAS2rest | 41.7±12.1 | 33.8±6.8 | 32.4±6. | 0.001* |
| 0.001† | ||||
| 0.427‡ | ||||
| VAS2mov | 46±11.1 | 38.3±6.5 | 37.43±6.1 | 0.002* |
| 0.001† | ||||
| 0.601‡ | ||||
| VAS4rest | 34.1±8.1 | 28.6±6.1 | 27.5±5.5 | 0.004* |
| 0.001† | ||||
| 0.495‡ | ||||
| VAS4mov | 40.±6.8 | 35.5±5.9 | 35.3±5.6 | 0.008* |
| 0.005† | ||||
| 0.93‡ | ||||
| VAS6rest | 27.6±5.4 | 24.9±4.9 | 18.5±4.7 | 0.049* |
| <0.001† | ||||
| <0.001‡ | ||||
| VAS6mov | 31.2±5.5 | 28±5.3 | 21.7±5.5 | 0.028* |
| <0.001† | ||||
| <0.001‡ | ||||
| VAS12rest | 19.8±5.9 | 18.4±3.8 | 14.2±4.6 | 0.28* |
| <0.001† | ||||
| <0.001‡ | ||||
| VAS12mov | 23.8±6 | 21.7±4.3 | 17.5±4.3 | 0.32* |
| <0.001† | ||||
| <0.001‡ | ||||
| VAS24rest | 13.9±3.9 | 13.2±2.7 | 11.9±2.9 | 0.413* |
| 0.035† | ||||
| 0.105‡ | ||||
| VAS24mov | 16.8±4.2 | 15.9±2.8 | 14.8±2.9 | 0.357* |
| 0.024† | ||||
| 0.077‡ |
*Level of significance between Group C and Group L, †Level of significance between Group C and Group LD, ‡Level of significance between Group L and Group LD. C=Control, L=Levobupivacaine, LD=Levobupivacaine dexmedetomidine group
Analgesic requirements (mean±standard deviation) in studied groups
| Group C | Group L | Group LD | ||
|---|---|---|---|---|
| Total pethidie dose | 102±24 | 64±19 | 36±9.8 | <0.001* |
| Time of first dose pethidine | 21±6 | 31±7 | 39±6 | <0.001* |
*Level of significance between Group C and Group L, †Level of significance between Group C and Group LD, ‡Level of significance between Group L and Group LD. C=Control, L=Levobupivacaine, LD=Levobupivacaine dexmedetomidine group
Patient satisfaction in the studied groups (numbers)
| Group C | Group L | Group LD | ||
|---|---|---|---|---|
| Fair | 8 | 0 | 0 | 0.001* |
| Poor | 19 | 2 | 1 | 0.001† |
| Good | 3 | 18 | 17 | 1‡ |
| Excellent | 0 | 10 | 12 |
*Level of significance between Group C and Group L, †Level of significance between Group C and Group LD, ‡Level of significance between Group L and Group LD. C=control, L=Levobupivacaine, LD=Levobupivacaine dexmedetomidine group
Postoperative adverse/side effects (%) in the studied groups
| Group C | Group L | Group LD | |
|---|---|---|---|
| Nausea | 1 | 1 | 1 |
| Vomiting | 2 | 1 | 0 |
| Itching | 0 | 0 | 0 |
C=Control, L=Levobupivacaine, LD=Levobupivacaine dexmedetomidine group